GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Christine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP
Professor, Pharmacy Practice and Clinical Pharmacist
Midwestern University

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.
2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.

0.1 CEU/1.0 Hr
UAN: 0107-0000-26-081-H01-P
Initial release date: 3/9/2026
Expiration date: 3/9/2027
Additional CPE details can be found here.